Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy in locally advanced colorectal cancer clinical research

ABSTRACT: Interventions: Case series:Apatinib Mesylate Tablets of joint mFOLFOX6 neoadjuant chemotherapy Primary outcome(s): pathologic complete response;Objective response rate;Drop period to ensure operation resection Study Design: Case series

DISEASE(S): Colorectal Cancer

PROVIDER: 2670768 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A prospective ,single arm, open study of Mesylate Apatinib combined with FOLFOX in the treatment of advanced colorectal cancer

Project description:Interventions: Case series:Mesylate Apatinib Primary outcome(s): R0 resection rate;AE Study Design: Case series

| 2676351 | ecrin-mdr-crc

Feasibility and safety study of apatinib mesylate in combination with s-1 for neoadjuvant treatment of colorectal cancer and postoperative management of s-1

Project description:Interventions: Case series:Preoperative apatinib combined with S-1, for the maintenance of postoperative S-1 Primary outcome(s): Total resection rate (R0 / R1 / R2);Two-year disease-free survival rate;Safty;PFS;PFS Study Design: Case series

| 2675770 | ecrin-mdr-crc

BA/BE study of Imatinib Mesylate 400 mg Tablets

Project description:Intervention1: Imatinib Mesylate 400mg Manufactured by Eugia Pharma Specialities Limited, India: This study will consists of two periods and is multiple dose study. Eligible patients will be administered with test (Imatinib Mesylate 400mg ) or reference (GleevecÂ (Imatinib Mesylate) Tablets 400 mg;)for 7 consecutive days in each period crossed over without washout. Control Intervention1: Gleevec(R) -Imatinib Mesylate 400mg Distributed by Novartis Pharmaceuticals Corporation, USA.: This study will consists of two periods and is multiple dose study. Eligible patients will be administered with test (Imatinib Mesylate 400mg ) or reference (GleevecÂ (Imatinib Mesylate) Tablets 400 mg;)for 7 consecutive days in each period crossed over without washout. Primary outcome(s): AUC0-ï?´ -: Area under the plasma concentration time curve over the steady state dosing interval. Cmax-ss: Maximum concentration over the steady state dosing interval. Timepoint: Day 1, 5, 6, 8, 12 and 13: Venous blood samples will be withdrawn 5 minutes prior to morning dosing to confirm steady state condition. ( 3 days/ 12 mL/ period) Day 7 and 14: Venous blood samples will be withdrawn at 0.00 (pre-dose) and 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 8.00, 12.00, 18.00 and 24.00 hours of post dose in each period. Study Design: Randomized, Crossover Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label

| 2577939 | ecrin-mdr-crc

Gene expression signature predictive of rapid response to imatinib mesylate in Gastrointestinal Stromal Tumor (GIST)

Project description:Gene expression profiling using oligonucleotide microarrays performed on tumor samples obtained before and after imatinib mesylate (IM) therapy. Rapid responding (to IM) samples were compared to non-responding/stable disease samples as measured by CT scan measurements to identify a gene signature that can predict rapid response to IM.

2009-11-24 | GSE15966 | GEO

A real-world study of apatinib mesylate in the treatment of locally advanced Colorectal cancer during the perioperative period

Project description:Interventions: Apatinib Mesylate Tablets group:None Primary outcome(s): R0 resection rate;Tumor regression grade Study Design: Single arm

| 35008 | ecrin-mdr-crc

Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer: single arm exploratory study

Project description:Interventions: Case series:Camrelizumab + Apatinib Primary outcome(s): Objective response rate Study Design: Single arm

| 2686078 | ecrin-mdr-crc

A single-arm, prospective, open-label clinical study of camrelizumab combined with apatinib mesylate as a third-line treatment for advanced colorectal cancer

Project description:Interventions: single arm:camrelizumab combined with apatinib mesylate Primary outcome(s): PFS Study Design: Single arm

| 2690370 | ecrin-mdr-crc

Transcription profiling of human gastrointestinal stromal tumour is predictive of rapid response to imatinib mesylate

2009-12-02 | E-GEOD-15966 | biostudies-arrayexpress

Clinical study for apatinib combined with tegafur in the treatment of advanced colorectal cancer and analysis of related prognostic factors

Project description:Interventions: Case series:Apatinib combined with tegafur Primary outcome(s): progression-free survival Study Design: Case series

| 2679969 | ecrin-mdr-crc

A prospective, open-label clinical study for apatinib combined with mFOLFOX6 chemotherapy in the treatment of postoperative colorectal cancer

Project description:Interventions: Case series:apatinib combined with mFOLFOX6 chemotherapy Primary outcome(s): Disease-free survival Study Design: Case series

| 2680256 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data